The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1261 articles
Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.
The FDA has issued a critical update to the drug facts label for Alli, the only over-the-counter weight loss medication available in the U.S. The changes highlight rare but potentially severe kidney-related side effects, prompting new warnings for consumers.
Novo Nordisk's Wegovy oral formulation has achieved unprecedented prescription rates, marking a pivotal shift in obesity care and intensifying competition with Eli Lilly.
Explore the groundbreaking REIMAGINE trial results for CagriSema, a novel dual-agonist therapy showing superior glycemic control and weight loss in type 2 diabetes patients.
The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.
Tennis legend Serena Williams is making waves both on and off the court. As she returns to professional tennis, advertisements featuring her advocacy for GLP-1 medications are set to air, highlighting a significant cultural moment for weight management therapies.
Actress Mayim Bialik's recent experience with severe gastrointestinal distress after starting a GLP-1 medication has brought a critical conversation to the forefront: the reality of significant side effects associated with these popular drugs. While GLP-1s offer profound benefits for many, understanding and managing potential adverse reactions is paramount.
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
GLP-1 medications, initially developed for diabetes, are revolutionizing health outcomes, offering remarkable benefits for inflammation, joint pain, and even mental outlook, alongside significant weight loss.
